Mabwell(SH:688062) ZHONGTAI SECURITIES·2026-02-25 08:32Investment Rating - The report assigns an "Buy" rating for the company, marking the first coverage of its stock [4]. Core Insights - The company, Maiwei Biopharmaceuticals, is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and clear innovation direction, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-research and business development (BD), leveraging its unique technology platforms and differentiated product pipelines to create value [2][4]. - The revenue forecast for the company shows significant growth, with projected revenues of 674 million RMB in 2025, 1.163 billion RMB in 2026, and 1.273 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of 238% from 2024 to 2025 [4]. Summary by Sections Company Overview - Maiwei Biopharmaceuticals has transitioned from a "generic-innovative" model to a "global innovation" approach, with plans for a Hong Kong IPO to support its sustainable development and international expansion [9]. - The company has a stable shareholding structure and an experienced management team, with a focus on drug development and commercialization [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work in synergy to achieve rapid innovation and differentiation [22][23]. - The pipeline is rich, with a focus on oncology products for immediate returns and anti-aging products for long-term growth [28]. Business Development Strategy - Maiwei has adopted a diversified and integrated approach to business development, forming partnerships to enhance product value and cash flow [4][19]. - The company is actively expanding its biosimilar drug business, which is crucial for cash flow, while also pursuing global market opportunities [4][19]. Financial Projections and Valuation - The company is expected to see a significant improvement in cash flow due to the anticipated success of its BD initiatives and the commercialization of its biosimilars [4]. - The estimated equity valuation of the company is 26.845 billion RMB, indicating that the current market valuation is undervalued [4].